Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such...
-- FDA Clears Initiation of Efficacy Trial in aHUS (Atypical Hemolytic Uremic Syndrome) Patients An Efficacy Trial in Adult aHUS...
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
Commercial launch planned for February 20, 2023BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical...
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...
Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ETRoivant will also participate in the SVB...
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continuesStrong data from Bentrio®...
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023...
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail,...
Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the...
SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments,...
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing...
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company...
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to...
BALTIMORE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and...
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline...